AbbVie doubles down on Gedeon Richter pact that brought Vraylar to the world
AbbVie doubles down on Gedeon Richter pact that brought Vraylar [...]
Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2
Histogen seeks to tear up COVID-19 R&D pact and go [...]
Harpoon drug sunk by modest activity, challenging tolerability, forcing pivot from prostate cancer prospect
Harpoon drug sunk by modest activity, challenging tolerability, forcing pivot [...]
Orphazyme on last leg as court-mediated restructuring drives another wave of layoffs
Orphazyme on last leg as court-mediated restructuring drives another wave [...]
MorphoSys cans US R&D to consolidate work in Germany, taking $254M charge
MorphoSys cans US R&D to consolidate work in Germany, taking [...]
Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot ‘expeditiously’
Selecta back in phase 1 gene therapy saddle after clinical [...]
Moderna doses 2nd arm of phase 2 booster study combining Spikevax with omicron-busting shot
Moderna doses 2nd arm of phase 2 booster study combining [...]
Roche-partnered Scenic Biotech snags $31M to study 3 rare disease drugs
Roche-partnered Scenic Biotech snags $31M to study 3 rare disease [...]
Morningside rolls up a pair of biotechs to birth clinical-phase inflammatory disease player
Morningside rolls up a pair of biotechs to birth clinical-phase [...]
Venatorx hits goal in antibiotic phase 3, clearing path to FDA
Venatorx hits goal in antibiotic phase 3, clearing path to [...]